AstraZeneca plc (LON:AZN) had its price target raised by Jefferies Group LLC from GBX 4,350 ($56.18) to GBX 4,800 ($61.99) in a research note released on Monday morning. They currently have a hold rating on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on AZN. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research note on Wednesday, June 21st. Deutsche Bank AG reduced their target price on AstraZeneca plc from GBX 5,700 ($73.61) to GBX 5,300 ($68.45) and set a buy rating for the company in a research note on Thursday, August 3rd. HSBC Holdings plc set a GBX 4,100 ($52.95) target price on AstraZeneca plc and gave the company a sell rating in a research note on Tuesday, August 8th. Liberum Capital restated a buy rating and issued a GBX 5,500 ($71.03) target price on shares of AstraZeneca plc in a research note on Monday, June 5th. Finally, Credit Suisse Group restated a neutral rating and issued a GBX 5,000 ($64.57) target price on shares of AstraZeneca plc in a research note on Monday, June 19th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of GBX 4,963.82 ($64.11).

Shares of AstraZeneca plc (AZN) opened at 4889.00 on Monday. The stock has a 50 day moving average price of GBX 4,571.40 and a 200-day moving average price of GBX 4,878.32. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The company’s market capitalization is GBX 61.89 billion.

AstraZeneca plc (LON:AZN) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $1.01. AstraZeneca plc had a return on equity of 14.36% and a net margin of 8.83%. On average, equities research analysts expect that AstraZeneca plc will post $3.75 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at

The business also recently declared a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were paid a dividend of GBX 68.90 ($0.89) per share. The ex-dividend date of this dividend was Thursday, August 10th. This represents a dividend yield of 1.35%.

In related news, insider Nazneen Rahman purchased 39 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.